GDP PROTOKOLÜ

Kaynaklar:

1- Crump, M., J. Kuruvilla, S. Couban, et al. 2014. "Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12." J Clin Oncol 32(31):3490-3496.

2- Villa, D., T. Seshadri, N. Puig, et al. 2012. "Second-line salvage chemotherapy for transplant-eligible patients with Hodgkin's lymphoma resistant to platinum-containing first-line salvage chemotherapy." Haematologica 97(5):751-757.

3- Moccia, A. A., F. Hitz, P. Hoskins, et al. 2017. "Gemcitabine, dexamethasone, and cisplatin (GDP) is an effective and well-tolerated salvage therapy for relapsed/refractory diffuse large B-cell lymphoma and Hodgkin lymphoma." Leuk Lymphoma 58(2):324-332.

4- Park, B. B., W. S. Kim, C. Suh, et al. 2015. "Salvage chemotherapy of gemcitabine, dexamethasone, and cisplatin (GDP) for patients with relapsed or refractory peripheral T-cell lymphomas: a consortium for improving survival of lymphoma (CISL) trial." Ann Hematol 94(11):1845-1851.